HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

BMY-25801, an antiemetic agent free of D2-dopamine receptor antagonist properties.

Abstract
BMY-25801, 4-amino-5-chloro-N-[2-(diethylamino)ethyl]2-(1-methyl-2-oxopropoxy ) benzamide, a new antiemetic agent free of D2-dopamine receptor antagonist properties, was effective against emesis induced by cytostatic agents (cisplatin, cyclophosphamide and doxorubicin) and total body radiation in the ferret. It also was effective against cisplatin-induced emesis in the dog; however, it was inactive against emesis caused by apomorphine and hydergine in the same species. In terms of activity profile, BMY-25801 could be differentiated both from metoclopramide and domperidone. Metoclopramide was nonselectively active against emesis induced by cytostatic agents, radiation and D2-dopamine receptor agonists, whereas domperidone was selectively effective against emesis induced by apomorphine and hydergine only. BMY-25801 failed to reveal any D2-dopamine receptor antagonist properties in several pharmacological tests (catalepsy, apomorphine stereotypy, serum prolactin, striatal dihydroxyphenylacetic acid and [3H]spiperone displacement) whereas metoclopramide was uniformly active in these tests. The activity profile of domperidone was compatible with its classification as a peripherally acting D2-dopamine receptor antagonist. BMY-25801 and metoclopramide antagonized serotonin-induced bradycardia (Bezold-Jarisch reflex) in the anesthetized rat, a response involving peripheral neuronal 5-HT3 receptors. Thus, BMY-25801 represents a novel antiemetic acting independently of D2-dopamine receptor mechanisms; however, its exact mode of action remains unknown.
AuthorsJ A Gylys, R N Wright, W D Nicolosi, J P Buyniski, R R Crenshaw
JournalThe Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther) Vol. 244 Issue 3 Pg. 830-7 (Mar 1988) ISSN: 0022-3565 [Print] United States
PMID2978041 (Publication Type: Journal Article)
Chemical References
  • Antiemetics
  • Receptors, Dopamine
  • Receptors, Dopamine D2
  • Receptors, Serotonin
  • batanopride
  • Doxorubicin
  • Cyclophosphamide
  • Metoclopramide
  • Apomorphine
  • Cisplatin
Topics
  • Animals
  • Antiemetics (pharmacology)
  • Apomorphine (antagonists & inhibitors)
  • Cisplatin (antagonists & inhibitors)
  • Cyclophosphamide (antagonists & inhibitors)
  • Dogs
  • Doxorubicin (antagonists & inhibitors)
  • Female
  • Ferrets
  • Male
  • Metoclopramide (analogs & derivatives, pharmacology)
  • Receptors, Dopamine (drug effects)
  • Receptors, Dopamine D2
  • Receptors, Serotonin (drug effects)
  • Reflex (drug effects)
  • Vomiting (etiology, prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: